Assessing the Frequency of Cytopenias in Patients with Hepatitis C Therapy: A descriptive Observational Study
DOI:
https://doi.org/10.37762/jgmds.13-2.892Keywords:
Hepatitis C, Direct-acting Antivirals, Ribavirin, Cytopenias, SVRAbstract
ABSTRACT
OBJECTIVES
This study aimed to determine the frequency of cytopenias among patients receiving hepatitis C therapy and to examine their relationship with different treatment regimens
METHODOLOGY
This descriptive Observational Study was conducted over six months (May-October 2024) at the Department of Medicine and Gastroenterology, Lady Reading Hospital, Peshawar. A total of 113 patients aged 20-70 years with chronic hepatitis C receiving antiviral therapy were included using consecutive sampling. Data were collected at the 12-week follow-up. Haematological parameters and sustained virological response (SVR) were assessed. Data were analysed using SPSS version 25. Chi-square test, Cramer’s V, and multivariate logistic regression were applied. A p-value ≤0.05 was considered statistically significant.
RESULTS
The mean age of participants was 40.1 ± 9.0 years, with a male predominance (55.8%). The overall SVR rate was 80.5%, with the highest response observed in patients treated with sofosbuvir/velpatasvir (90.8%; 95% CI: 82.1-96.2). Cytopenias were observed in a considerable proportion of patients, with anemia being the most common (23.9%; 95% CI: 16.1-31.7), followed by Thrombocytopenia (9.7%), leukopenia (8.8%), and pancytopenia (6.2%).
A statistically significant association was found between treatment regimen and cytopenias (p < 0.001), with a strong effect size for anemia (Cramer’s V = 0.768). Multivariate analysis identified treatment regimen as the only independent predictor of anemia. Patients receiving sofosbuvir/velpatasvir had significantly lower odds of anemia than those receiving conventional therapy (AOR = 0.006; 95% CI: 0.001-0.054; p < 0.001).
CONCLUSION
Direct-acting antiviral therapy, particularly sofosbuvir/velpatasvir, is associated with high virological response and a lower frequency of cytopenias. However, given the observational design, findings should be interpreted cautiously. Further multicenter studies are recommended.
Downloads
Metrics
References
Tariq EB, et al. Frequency of Thrombocytopenia in patients infected with hepatitis C virus in a tertiary care hospital. J Health Rehabil Res. 2024;4(3):1-9. https://doi.org/10.61919/jhrr.v4i3.1250 DOI: https://doi.org/10.61919/jhrr.v4i3.1250
Ayaz QUA, et al. Pattern and burden of Thrombocytopenia in chronic hepatitis C virus patients at a tertiary care hospital. Pak J Pathol. 2024;35(1):39-43. https://doi.org/10.55629/pakjpathol.v35i1.796 DOI: https://doi.org/10.55629/pakjpathol.v35i1.796
Laursen TL, et al. Liver-related effects of chronic hepatitis C antiviral treatment. World J Gastroenterol. 2020;26(22):2931-47. https://doi.org/10.3748/wjg.v26.i22.2931 PMID: 32587445 DOI: https://doi.org/10.3748/wjg.v26.i22.2931
Wong YJ, et al. Real-world treatment outcome with protease inhibitor direct-acting antiviral in advanced hepatitis C cirrhosis: REAL-C study. Hepatol Int. 2023;17(5):1150-61. https://doi.org/10.1007/s12072-023-10547-4 PMID: 37414569 DOI: https://doi.org/10.1007/s12072-023-10547-4
Iida J, et al. CCL19/MIP-3β as a mediator in anti-GPIIb/IIIa antibody-producing B cells in chronic hepatitis C. Cytokine. 2025;190:156915. https://doi.org/10.1016/j.cyto.2025.156915 (PMID not yet indexed) DOI: https://doi.org/10.1016/j.cyto.2025.156915
Salama II, et al. Impact of direct-acting antivirals on hepatic and extrahepatic manifestations of hepatitis C virus infection. World J Hepatol. 2022;14(6):1053-73. https://doi.org/10.4254/wjh.v14.i6.1053 PMID: 35795664 DOI: https://doi.org/10.4254/wjh.v14.i6.1053
Amin R, et al. Seroprevalence and risk factors of hepatitis C in Nowshera District, Pakistan. Sci Rep. 2024;14(1):25613. https://doi.org/10.1038/s41598-024-76677-3 PMID: 39101084 DOI: https://doi.org/10.1038/s41598-024-76677-3
Akhtar S, Nasir JA, Hinde A. Prevalence of hepatitis C virus infection in β-thalassemia patients in Pakistan: a systematic review and meta-analysis. BMC Public Health. 2020;20(1):587. https://doi.org/10.1186/s12889-020-8414-5 PMID: 32366274. DOI: https://doi.org/10.1186/s12889-020-8414-5
Piracha ZZ, et al. Prevalence and clinical profile of hepatitis C virus infection in multitransfused thalassemic patients in Pakistan. Braz J Biol. 2024;84. (DOI/PMID not indexed) DOI: https://doi.org/10.1590/1519-6984.284453
Sood AK, et al. Epidemiology of hepatitis C virus infection in a tertiary care hospital. Med J Armed Forces India. 2020;76(4):443-50. https://doi.org/10.1016/j.mjafi.2019.08.003 PMID: 33223588 DOI: https://doi.org/10.1016/j.mjafi.2019.08.003
Cappellini MD, Motta I. Anemia in clinical practice: definition and classification. Semin Hematol. 2015;52(4):261-9. https://doi.org/10.1053/j.seminhematol.2015.07.006 PMID: 26404438 DOI: https://doi.org/10.1053/j.seminhematol.2015.07.006
Mushtaq S, et al. Efficacy and safety of sofosbuvir plus daclatasvir and sofosbuvir/velpatasvir in HCV genotype 3 patients: real-world outcomes from Pakistan. Front Pharmacol. 2020;11:550205. https://doi.org/10.3389/fphar.2020.550205 PMID: 32982917 DOI: https://doi.org/10.3389/fphar.2020.550205
Lampertico P, et al. Effectiveness and safety of glecaprevir/pibrentasvir in chronic HCV infection: a meta-analysis. J Hepatol. 2020;72(6):1112-21. https://doi.org/10.1016/j.jhep.2020.01.025 PMID: 32068127 DOI: https://doi.org/10.1016/j.jhep.2020.01.025
Margusino-Framiñán L, et al. Influence of drug–drug interactions on direct-acting antivirals for hepatitis C. Eur J Hosp Pharm. 2021;28(1):16-21. https://doi.org/10.1136/ejhpharm-2019-001889 PMID: 31704894 DOI: https://doi.org/10.1136/ejhpharm-2019-001889
Zoratti MJ, et al. Pangenotypic direct-acting antivirals for chronic hepatitis C: a systematic review and meta-analysis. EClinicalMedicine. 2020;18:100237. https://doi.org/10.1016/j.eclinm.2019.12.007 PMID: 31993549 DOI: https://doi.org/10.1016/j.eclinm.2019.12.007
Xia H, et al. Efficacy and safety of direct-acting antivirals in chronic hepatitis C: real-world study from China. Front Pharmacol. 2020;11:710. https://doi.org/10.3389/fphar.2020.00710 PMID: 32581977 DOI: https://doi.org/10.3389/fphar.2020.00710
Dietz C, Maasoumy B. Direct-acting antiviral agents for hepatitis C virus infection. Viruses. 2022;14(6):1325. https://doi.org/10.3390/v14061325 PMID: 35743864 DOI: https://doi.org/10.3390/v14061325
Schulte B, et al. Outcomes of direct-acting antivirals in patients on opioid agonist treatment. Open Forum Infect Dis. 2020;7(8):ofaa317. https://doi.org/10.1093/ofid/ofaa317 PMID: 32766265 DOI: https://doi.org/10.1093/ofid/ofaa317
European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C: final update. J Hepatol.2020;73(5):1170-218. https://doi.org/10.1016/j.jhep.2020.08.018 PMID: 32956768 DOI: https://doi.org/10.1016/j.jhep.2020.08.018
World Health Organization. Guidelines for the screening, care and treatment of persons with hepatitis C infection. Geneva: WHO; 2014
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Shadman Ahmad Jan, Naveed Iqbal, Ilyas Muhammad, Zahid ullah, Ijaz Hussain
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
